Target-selective drug delivery remains a challenge for various therapeutic applications and particularly for cancer. Current targeting strategies include formulation and encapsulation for preferential release in the acidic tumor environment as well as covalent conjugation via linkers sensitive to pH, to oxygen levels, or to disease-specific enzymes. These approaches have been limited by:
A new class of linkers has been developed to address these limitations. These linkers:
These features should prove extremely relevant for clinical applications, from cancer to ophthalmology, where increased efficacy and reduce drug toxicity can enhance the therapeutic profile and/or extend patient life for promising and useful drugs.
See issued patent, below.
|United States Of America||Issued Patent||8,575,359||11/05/2013||2006-140|
tumor, selective delivery, targeted, targeted delivery, carrier, linker, cancer, ophthalmology, macular degeneration, retinopathy, sustained release, controlled release